Table 2.
Base case results on costs and health effects (cases, deaths and QALYs) per infant of incorporating a measles dose in China at 4, 5, 6 or 7 months of age compared to ‘do nothing’┼
| Measles cases | 4 months | - | 0.00036 | −0.00092 |
| 5 months | - | 0.00038 | −0.00090 | |
| 6 months | - | 0.00042 | −0.00086 | |
| 7 months | - | 0.00055 | −0.00072 | |
| 8 months (comparator) | 0.0012776 | - | - | |
| Measles deaths | 4 months | - | 0.0000005 | −0.0000013 |
| 5 months | - | 0.0000005 | −0.0000012 | |
| 6 months | - | 0.0000006 | −0.0000012 | |
| 7 months | - | 0.0000008 | −0.0000010 | |
| 8 months (comparator) | 0.0000017 | - | - | |
| QALY | 4 months | - | 30.8435 | 0.01630 |
| 5 months | - | 30.8431 | 0.01591 | |
| 6 months | - | 30.8423 | 0.01515 | |
| 7 months | - | 30.8400 | 0.01279 | |
| 8 months (comparator) | 30.8272 | - | ||
| Vaccination program costs (US$) | 4 months | - | $ 4.30 | $ 4.30 |
| 5 months | - | $ 4.29 | $ 4.29 | |
| 6 months | - | $ 4.28 | $ 4.28 | |
| 7 months | - | $ 4.27 | $ 4.27 | |
| 8 months (comparator) | - | - | - | |
| Healthcare costs (US$) | 4 months | - | $ 0.20 | $ (0.51) |
| 5 months | - | $ 0.21 | $ (0.50) | |
| 6 months | - | $ 0.23 | $ (0.47) | |
| 7 months | - | $ 0.31 | $ (0.40) | |
| 8 months (comparator) | $ 0.70 | - | - | |
| Net costs, i.e. the sum of program and healthcare costs (US$) | 4 months | - | $ 4.50 | $ 3.79 |
| 5 months | - | $ 4.50 | $ 3.79 | |
| 6 months | - | $ 4.51 | $ 3.81 | |
| 7 months | - | $ 4.57 | $ 3.87 | |
| 8 months (comparator) | $ 0.70 | - | $ - |
Cost and health effects compare adding a ‘0 dose’ to the current Chinese measles vaccination schedule at 4, 5, 6 or 7 months of age to the current Chinese measles vaccination schedule alone (2 doses at 8 and 18 months). Costs and health effects are measured for children 4–8 months with and without the alternative policy change of vaccinating with a ‘0 dose’ at 4, 5, 6 or 7 months. Health and economic consequences associated with the alternative scenarios (adding a measles dose at 4, 5, 6 or 7 months) are compared to the observed number of cases at 8 months of age in the presence of the current schedule and the modeled number of clinical events and costs associated with the existing burden.